GLPwatch
Papers (10389)
Page 161 of 174, ranked by citation count.
- Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.
- GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.
- Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
- Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.
- Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review.
- Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
- Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status.
- Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.
- Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes.
- The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs.
- GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications.
- Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
- [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.
- Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.
- Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.
- [Liraglutid can support weight loss].
- Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.
- Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.
- GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.
- Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
- Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
- Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.
- Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.
- Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.
- Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.
- [Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?]
- [Basal insulin and liraglutide combined in a pen].
- Metabolic inflammation at the adipose-brain axis.
- Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights.
- Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.
- Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.
- Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
- Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"
- Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro.
- [Nephrology : what's new in 2025].
- Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.
- Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation.
- [GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells].
- [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
- Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming.
- SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Obesity Management: Pharmacotherapy.
- [<sup>18</sup>F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.
- Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.
- The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat.
- Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.
- GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge.
- Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.
- New drugs 2015, part 3.
- [Liraglutide improves cardiac structure and function in mice with advanced diabetic nephropathy and massive proteinuria].
- [New outcome studies with injectable semaglutide in different at risk populations].
- The Novel Tetra-Specific Drug C-192, Conjugated Using UniStac, Alleviates Non-Alcoholic Steatohepatitis in an MCD Diet-Induced Mouse Model.
- Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.
- Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.
- Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights.
- ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
- GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.